The statistical analysis of wound healing assay of WT-KRAS CRC cells (Fig. 6d) further demonstrated that after treatment with cetuximab the migration capacities of cells with no circIFNGR2 transfected were significantly lessened while these capacities of cells in circIFNGR2 overexpression group were not influenced observably. The gene discussed is KRAS; the disease is colorectal carcinoma.